CEA promoter-regulated oncolytic adenovirus-mediated Hsp70 expression in immune gene therapy for pancreatic cancer

Cancer Letters

Volumn 319, Issue 2, 2012, Pages 154-163

  Xu, Can ^a   Sun, Yunliang ^a   Wang, Yunfeng ^a   Yan, Yan ^b   Shi, Zhengjie ^b   Chen, Lei ^b   Lin, Han ^a   Lü, Shunli ^a   Zhu, Maoling ^a   Su, Changqing ^b   Li, Zhaoshen ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Adenovirus; Carcinoembryonic antigen; Heat shock protein; Immunogene therapy; Pancreatic cancer

Indexed keywords

ADENOVIRUS VECTOR; CARCINOEMBRYONIC ANTIGEN; GAMMA INTERFERON; HEAT SHOCK PROTEIN 70; INTERLEUKIN 6; ONCOLYTIC ADENOVIRUS VECTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLOGY; EMBRYO; GAMMA DELTA T LYMPHOCYTE; GENE; HSP70 GENE; HUMAN; HUMAN CELL; IMMUNE GENE THERAPY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPORTER GENE; TUMOR XENOGRAFT; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; GENE THERAPY; GENETIC VECTORS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; INTERLEUKIN-6; MALE; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; PANCREATIC NEOPLASMS; PROMOTER REGIONS, GENETIC; RATS; TRANSFORMING GROWTH FACTOR BETA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; MUS MUSCULUS; RATTUS;

EID: 84862806928     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.01.009     Document Type: Article

References (49)

1. Hart A.R., Kennedy H., Harvey I. Pancreatic cancer: a review of the evidence on causation. Clin. Gastroenterol. Hepatol. 2008, 6:275-282.
2. J. Gene Med., Gene Therapy Clinical Trials Worldwide, <> (updated June 2011) (accessed 22.09.2011. http://www.wiley.com//legacy/wileychi/genmed/clinical.
3. Blaese R.M. Development of gene therapy for immunodeficiency: adenosine deaminase deficiency. Pediatr. Res. 1993, 33:S49-S53.
4. discussion S53-S55.
5. Anderson W.F., Blaese R.M., Culver K. The ADA human gene therapy clinical protocol: points to consider response with clinical protocol, July 6, 1990. Hum. Gene Ther. 1990, 1:331-362.
6. Cideciyan A.V., Hauswirth W.W., Aleman T.S., Kaushal S., Schwartz S.B., Boye S.L., Windsor E.A., Conlon T.J., Sumaroka A., Roman A.J., Byrne B.J., Jacobson S.G. Vision 1year after gene therapy for Leber's congenital amaurosis. N. Engl. J. Med. 2009, 361:725-727.
7. Cartier N., Hacein-Bey-Abina S., Bartholomae C.C., Veres G., Schmidt M., Kutschera I., Vidaud M., Abel U., Dal-Cortivo L., Caccavelli L., Mahlaoui N., Kiermer V., Mittelstaedt D., Bellesme C., Lahlou N., Lefrère F., Blanche S., Audit M., Payen E., Leboulch P., l'Homme B., Bougnères P., Von Kalle C., Fischer A., Cavazzana-Calvo M., Aubourg P. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009, 326:818-823.
8. Christine C.W., Starr P.A., Larson P.S., Eberling J.L., Jagust W.J., Hawkins R.A., VanBrocklin H.F., Wright J.F., Bankiewicz K.S., AminoffJ M. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009, 73:1662-1669.
9. Lees A.J., Hardy J., Revesz T. Parkinson's disease. Lancet 2009, 373:2055-2066.
10. Sakai R., Kagawa S., Yamasaki Y., Kojima T., Uno F., Hashimoto Y., Watanabe Y., Urata Y., Tanaka N., Fujiwara T. Preclinical evaluation of differentially targeting dual virotherapy for human solid cancer. Mol. Cancer Ther. 2010, 9:1884-1893.
11. Pesonen S., Kangasniemi L., Hemminki A. Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol. Pharm. 2011, 8:12-28.
12. Takaoka H., Takahashi G., Ogawa F., Imai T., Iwai S., Yura Y. A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma. Virol. J. 2011, 8:294.
13. Sakurai F., Katayama K., Mizuguchi H. MicroRNA-regulated transgene expression systems for gene therapy and virotherapy. Front. Biosci. 2011, 17:2389-2401.
14. Chen L., Chen D., Manome Y., Dong Y., Fine H.A., Kufe D.W. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J. Clin. Invest. 1995, 96:2775-2782.
15. Ma J., He X., Wang W., Huang Y., Chen L., Wong C., Gu J., Hu H., Shi J., Li L., Su C. E2F promoter-regulated oncolytic adenovirus with p16 gene induces cell apoptosis and exerts antitumor effect on gastric cancer. Dig. Dis. Sci. 2009, 54:1425-1431.
16. Ma S.H., Chen G.G., Yip J., Lai P.B. Therapeutic effect of alpha-fetoprotein promoter-mediated tBid and chemotherapeutic agents on orthotopic liver tumor in mice. Gene Ther. 2010, 17:905-912.
17. Cao G., Zhang X., He X., Chen Q., Qi Z. A safe effective in vivo gene therapy for melanoma using tyrosinase promoter-driven cytosine deaminase gene. In Vivo 1999, 13:181-187.
18. Naito Y., Okabe Y., Nagayama M., Nishinakagawa T., Taira T., Kawahara A., Hattori S., Machida K., Ishida Y., Kaji R., Mikagi K., Kinoshita H., Yasumoto M., Akiba J., Kage M., Nakashima M., Ohshima K., Yano H. Accuracy of differential diagnosis for pancreatic cancer is improved in the combination of RCAS1 and CEA measurements and cytology in pancreatic juice. Med. Mol. Morphol. 2011, 44:86-92.
19. Mehta J., Prabhu R., Eshpuniyani P., Kantharia C., Supe A. Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies. Trop. Gastroenterol. 2010, 31:190-194.
20. Hanahan D., Weinberg R.A. Hallmarks of cancer, the next generation. Cell 2011, 144:646-674.
21. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
22. Multhoff G. Heat shock proteins in immunity. Handb. Exp. Pharmacol. 2006, 172:279-304.
23. Tsan M.F., Gao B. Heat shock protein and innate immunity. Cell Mol. Immunol. 2004, 1:274-279.
24. Srivastava P.K., Udono H., Blachere N.E., Li Z. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 1994, 39:93-98.
25. Haug M., Dannecker L., Schepp C.P., Kwok W.W., Wernet D., Buckner J.H., Kalbacher H., Dannecker G.E., Holzer U. The heat shock protein Hsp70 enhances antigen-specific proliferation of human CD4+ memory T cells. Eur. J. Immunol. 2005, 35:3163-3172.
26. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells, chaperoning of the innate and adaptive immune responses. Ann. Rev. Immunol. 2002, 20:395-425.
27. Morse M.A., Clay T.M., Hobeika A.C., Osada T., Khan S., Chui S., Niedzwiecki D., Panicali D., Schlom J., Lyerly H.K. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin. Cancer Res. 2005, 11:3017-3024.
28. Kim T.W., Lee J.H., He L., Boyd D.A., Hung C.F., Wu T.C. DNA vaccines employing intracellular targeting strategies and a strategy to prolong dendritic cell life generate a higher number of CD8+ memory T cells and better long-term antitumor effects compared with a DNA prime-vaccinia boost regimen. Hum. Gene Ther. 2005, 16:26-34.
29. Rupik W., Jasik K., Bembenek J., Widłak W. The expression patterns of heat shock genes and proteins and their role during vertebrate's development. Comp. Biochem. Physiol. A: Mol. Integr. Physiol. 2011, 159:349-366.
30. Madrigal-Matute J., Martin-Ventura J.L., Blanco-Colio L.M., Egido J., Michel J.B., Meilhac O. Heat-shock proteins in cardiovascular disease. Adv. Clin. Chem. 2011, 54:1-43.
31. Chen T., Guo J., Han C., Yang M., Cao X. Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway. J. Immunol. 2009, 182:1449-1459.
32. Huang C., Yu H., Wang Q., Ma W., Xia D., Yi P., Zhang L., Cao X. Potent antitumor effect elicited by superantigen-linked tumor cells transduced with heat shock protein 70 gene. Cancer Sci. 2004, 95:160-167.
33. Chen X., Tao Q., Yu H., Zhang L., Cao X. Tumor cell membrane-bound heat shock protein 70 elicits antitumor immunity. Immunol. Lett. 2002, 84:81-87.
34. Yamaoka A., Guan X., Takemoto S., Nishikawa M., Takakura Y. Development of a novel Hsp70-based DNA vaccine as a multifunctional antigen delivery system. J. Control. Release 2010, 142:411-415.
35. Eager R.M., Nemunaitis J. Clinical development directions in oncolytic viral therapy. Cancer Gene Ther. 2011, 18:305-317.
36. Breitbach C.J., Burke J., Jonker D., Stephenson J., Haas A.R., Chow L.Q., Nieva J., Hwang T.H., Moon A., Patt R., Pelusio A., Le Boeuf F., Burns J., Evgin L., De Silva N., Cvancic S., Robertson T., Je J.E., Lee Y.S., Parato K., Diallo J.S., Fenster A., Daneshmand M., Bell J.C., Kirn D.H. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011, 477:99-102.
37. Agarwalla P.K., Aghi M.K. Oncolytic herpes simplex virus engineering and preparation. Methods Mol. Biol. 2012, 797:1-19.
38. Thorne S.H. Next-generation oncolytic vaccinia vectors. Methods Mol. Biol. 2012, 797:205-215.
39. Shmulevitz M., Lee P.W. Exploring host factors that impact reovirus replication, dissemination, and reovirus-induced cell death in cancer versus normal cells in culture. Methods Mol. Biol. 2012, 797:163-176.
40. Vile R. Oncolytic viruses, now interviewing for the all-star game. Mol. Ther. 2010, 18:866-868.
41. Park K., Kim W.J., Cho Y.H., Lee Y.I., Lee H., Jeong S., Cho E.S., Chang S.I., Moon S.K., Kang B.S., Kim Y.J., Cho S.H. Cancer gene therapy using adeno-associated virus vectors. Front. Biosci. 2008, 13:2653-2659.
42. Tai C.K., Kasahara N. Replication-competent retrovirus vectors for cancer gene therapy. Front. Biosci. 2008, 13:3083-3095.
43. Tysome J.R., Wang P., Alusi G., Briat A., Gangeswaran R., Wang J., Bhakta V., Fodor I., Lemoine N.R., Wang Y. Lister vaccine strain of vaccinia virus armed with the endostatin-angiostatin fusion gene, an oncolytic virus superior to dl1520 (ONYX-015) for human head and neck cancer. Hum. Gene Ther. 2011, 22:1101-1108.
44. Fang L., Huang Y., Hu X., Sun L., He X., Hu H., Pu Y., Cao X., Luo H., Pan S., Gu J., Su C. A truncated minimal-E1a gene with potency to support adenoviral replication mediates antitumor activity by down-regulating Neu expression and preserving Rb function. Chem. Biol. Interact. 2009, 181:1-7.
45. Su C., Peng L., Sham J., Wang X., Zhang Q., Chua D., Liu C., Cui Z., Xue H., Wu H., Yang Q., Zhang B., Liu X., Wu M., Qian Q. Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice. Mol. Ther. 2006, 13:918-927.
46. Su C., Na M., Chen J., Wang X., Liu Y., Wang W., Zhang Q., Li L., Long J., Liu X., Wu M., Fan X., Qian Q. Gene-viral cancer therapy using dual-regulated oncolytic adenovirus with antiangiogenesis gene for increased efficacy. Mol. Cancer Res. 2008, 6:568-575.
47. Hu H., Li Z., Chen J., Wang D., Ma J., Wang W., Li J., Wu H., Li L., Wu M., Qian Q., Chen J., Su C. P16 reactivation induces anoikis and exhibits antitumour potency by downregulating Akt/survivin signalling in hepatocellular carcinoma cells. Gut 2011, 60:710-721.
48. Adams W.C., Gujer C., McInerney G., Gall J.G., Petrovas C., Karlsson Hedestam G.B., Koup R.A., Loré K. Adenovirus type-35 vectors block human CD4±T-cell activation via CD46 ligation. Proc. Natl. Acad. Sci. USA 2011, 108:7499-7504.
49. Brand R.E., Nolen B.M., Zeh H.J., Allen P.J., Eloubeidi M.A., Goldberg M., Elton E., Arnoletti J.P., Christein J.D., Vickers S.M., Langmead C.J., Landsittel D.P., Whitcomb D.C., Grizzle W.E., Lokshin A.E. Serum biomarker panels for the detection of pancreatic cancer. Clin. Cancer Res. 2011, 17:805-816.